nach oben

12.02.2019 | Original Article | Ausgabe 4/2019

Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure

Zeitschrift:: Journal of Cardiovascular Translational Research > Ausgabe 4/2019

Autoren:: Jasmine A. Luzum, Joseph D. English, Umair S. Ahmad, Jessie W. Sun, Benjamin D. Canan, Wolfgang Sadee, Joseph P. Kitzmiller, Philip F. Binkley

Ergänzende Inhalte

» Jetzt Zugang zum Volltext erhalten

Wichtige Hinweise

Associate Editor Paul J. R. Barton oversaw the review of this article

Electronic supplementary material

The online version of this article (https://doi.org/10.1007/s12265-019-09866-5) contains supplementary material, which is available to authorized users.

Dedication

In sorrow, we would like to dedicate this work to our friend and co-author, Joseph P. Kitzmiller. Dr. Kitzmiller passed away on October 3, 2018, shortly before our submission of this paper.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Two common genetic polymorphisms in the beta-1 adrenergic receptor (ADRB1 Ser49Gly [rs1801252] and Arg389Gly [rs1801253]) significantly affect receptor function in vitro. The objective of this study was to determine whether ADRB1 Ser49Gly and Arg389Gly are associated with recovery of left ventricular ejection fraction (LVEF) in patients with heart failure. Patients with heart failure and baseline LVEF ≤ 40% were genotyped (n = 98), and retrospective chart review assessed the primary outcome of LVEF recovery to ≥ 40%. Un/adjusted logistic regression models revealed that Ser49Gly, but not Arg389Gly, was significantly associated with LVEF recovery in a dominant genetic model. The adjusted odds ratio for Ser49 was 8.2 (95% CI = 2.1–32.9; p = 0.003), and it was the strongest predictor of LVEF recovery among multiple clinical variables. In conclusion, patients with heart failure and reduced ejection fraction that are homozygous for ADRB1 Ser49 were significantly more likely to experience LVEF recovery than Gly49 carriers.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

★ PREMIUM-INHALT

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med bestellen und 100 € sparen!

Jetzt gratis testen * Jetzt kaufen

Sie können e.Med Interdisziplinär 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt testen ¹

ESM 1 (DOCX 17 kb)

ESM 2 (DOCX 18 kb)

ESM 3 (DOCX 14 kb)

Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., et al. (2018). Heart disease and stroke statistics—2018 update: a report from the American Heart Association (review-article). Circulation, 137(12), e67–e492. https://doi.org/10.1161/CIR.0000000000000558. CrossRefPubMed

Lupón, J., Díez-López, C., de Antonio, M., Domingo, M., Zamora, E., Moliner, P., et al. (2017). Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. European Journal of Heart Failure, 19(12), 1615–1623. https://doi.org/10.1002/ejhf.824. CrossRefPubMed

Teeter, W. A., Thibodeau, J. T., Rao, K., Brickner, M. E., Toto, K. H., Nelson, L. L., et al. (2012). The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: Implications for timing of implantable cardioverter-defibrillator implantation. American Heart Journal, 164(3), 358–364. https://doi.org/10.1016/j.ahj.2012.06.009. CrossRefPubMed

Merlo, M., Caiffa, T., Gobbo, M., Adamo, L., & Sinagra, G. (2018). Reverse remodeling in dilated cardiomyopathy: insights and future perspectives. International Journal of Cardiology: Heart & Vasculature, 18, 52–57. https://doi.org/10.1016/j.ijcha.2018.02.005. CrossRef

Mann, D., Kent, R., Parsons, B., & Cooper, G. (1992). Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation, 85(2), 790–804. https://doi.org/10.1161/01.CIR.85.2.790. CrossRefPubMed

MERIT-HF Study Group. (1999). Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). The Lancet, 353(9169), 2001–2007. https://doi.org/10.1016/S0140-6736(99)04440-2. CrossRef

Hernandez, A. F., Hammill, B. G., O'Connor, C. M., Schulman, K. A., Curtis, L. H., & Fonarow, G. C. (2009). Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry. Journal of the American College of Cardiology, 53(2), 184. https://doi.org/10.1016/j.jacc.2008.09.031. CrossRefPubMedPubMedCentral

Podlowski, S., Wenzel, K., Luther, H. P., Müller, J., Bramlage, P., Baumann, G., et al. (2000). β1-Adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? Journal of Molecular Medicine, 78(2), 87–93. https://doi.org/10.1007/s001090000080. CrossRefPubMed

Rathz, D. A., Brown, K. M., Kramer, L. A., & Liggett, S. B. (2002). Amino acid 49 polymorphisms of the human [beta] 1-adrenergic receptor affect agonist-promoted trafficking. Journal of Cardiovascular Pharmacology, 39(2), 155–160. CrossRefPubMed

10.

Liggett, S. B., Mialet-Perez, J., Thaneemit-Chen, S., Weber, S. A., Greene, S. M., Hodne, D., et al. (2006). A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences, 103(30), 11288–11293. https://doi.org/10.1073/pnas.0509937103. CrossRef

11.

Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62(16), e147–e239. https://doi.org/10.1016/j.jacc.2013.05.019. CrossRefPubMed

12.

Binkley, P. F., Lesinski, A., Ferguson, J. P., Hatton, P. S., Yamokoski, L., Hardikar, S., et al. (2008). Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an increasingly prevalent clinical event. American Heart Journal, 155(1), 69–74. https://doi.org/10.1016/j.ahj.2007.08.010. CrossRefPubMed

13.

Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research, 16(3), 1215–1215. https://doi.org/10.1093/nar/16.3.1215. CrossRefPubMedPubMedCentral

14.

1000 Genomes Project, C. (2015). A global reference for human genetic variation (article). Nature, 526, 68. https://doi.org/10.1038/nature15393. CrossRef

15.

Lanfear, D. E., Peterson, E. L., Zeld, N., Wells, K., Sabbah, H. N., & Williams, K. (2015). Beta blocker survival benefit in heart failure is associated with ADRB1 Ser49Gly genotype. Journal of Cardiac Failure, 21(8, Supplement), S50. https://doi.org/10.1016/j.cardfail.2015.06.169. CrossRef

16.

Talameh, J., Garrand, A., Ghali, J., Oren, R. M., Dunlap, S., Bakel, A. V., et al. (2012). Beta-1 adrenergic receptor genotype Ser49Gly is associated with beta-blocker survival benefit in patients with heart failure. Journal of the American College of Cardiology, 59(13, Supplement), E861. https://doi.org/10.1016/S0735-1097(12)60862-6. CrossRef

17.

Levin, M. C., Marullo, S., Muntaner, O., Andersson, B., & Magnusson, Y. (2002). The myocardium-protective Gly-49 variant of the β1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. Journal of Biological Chemistry, 277(34), 30429–30435. https://doi.org/10.1074/jbc.M200681200. CrossRefPubMed

18.

Terra, S. G., Hamilton, K. K., Pauly, D. F., Lee, C. R., Patterson, J. H., Adams, K. F., et al. (2005). Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenetics and Genomics, 15(4), 227. CrossRefPubMed

19.

de Groote, P., Helbecque, N., Lamblin, N., Hermant, X., Mc Fadden, E., Foucher-Hossein, C., et al. (2005). Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and Genomics, 15(3), 137–142. https://doi.org/10.1097/01213011-200503000-00001. CrossRefPubMed

20.

Nonen, S., Okamoto, H., Fujio, Y., Takemoto, Y., Yoshiyama, M., Hamaguchi, T., et al. (2008). Polymorphisms of norepinephrine transporter and adrenergic receptor α1D are associated with the response to β-blockers in dilated cardiomyopathy. The Pharmacogenomics Journal, 8(1), 78–84. https://doi.org/10.1038/sj.tpj.6500450. CrossRefPubMed

21.

Chen, L., Meyers, D., Javorsky, G., Burstow, D., Lolekha, P., Lucas, M., et al. (2007). Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and Genomics, 17(11), 941. https://doi.org/10.1097/FPC.0b013e3282ef7354. CrossRefPubMed

22.

Perez, J. M., Rathz, D. A., Petrashevskaya, N. N., Hahn, H. S., Wagoner, L. E., Schwartz, A., et al. (2003). [Beta]1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature Medicine, 9(10), 1300. https://doi.org/10.1038/nm930. CrossRef

23.

Luo, M., Bi, Y., & Xu, Y. X. (2007). Effects of metoprolol on beta1 adrenergic receptor polymorphism and receptor density in urban Chinese patients with heart failure. Chinese Medical Journal, 120(19), 1720–1723. CrossRefPubMed

24.

Hu, H., Jui, H.-Y., Hu, F.-C., Chen, Y.-H., Lai, L.-P., & Lee, C.-M. (2007). Predictors of therapeutic response to beta-blockers in patients with heart failure in Taiwan. Journal of the Formosan Medical Association, 106(8), 641–648. https://doi.org/10.1016/S0929-6646(08)60021-2. CrossRefPubMed

25.

Metra, M., Covolo, L., Pezzali, N., Zacà, V., Bugatti, S., Carlo, L., et al. (2010). Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovascular Drugs and Therapy, 24(1), 49–60. https://doi.org/10.1007/s10557-010-6220-5. CrossRefPubMed

26.

Borjesson, M., Magnusson, Y., Hjalmarson, A., & Andersson, B. (2000). A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure. European Heart Journal, 21(22), 1853–1858. https://doi.org/10.1053/euhj.1999.1994. CrossRefPubMed

27.

Magnusson, Y., Levin, M. C., Eggertsen, R., Nyström, E., Mobini, R., Schaufelberger, M., et al. (2005). Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clinical Pharmacology and Therapeutics, 78(3), 221. https://doi.org/10.1016/j.clpt.2005.06.004. CrossRefPubMed

28.

Cresci, S., Kelly, R. J., Cappola, T. P., Diwan, A., Dries, D., Kardia, S. L., et al. (2009). Clinical and genetic modifiers of long-term survival in heart failure. Journal of the American College of Cardiology, 54(5), 432–444. https://doi.org/10.1016/j.jacc.2009.05.009. CrossRefPubMedPubMedCentral

29.

Sehnert, A. J., Daniels, S. E., Elashoff, M., Wingrove, J. A., Burrow, C. R., Horne, B., et al. (2008). Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. Journal of the American College of Cardiology, 52(8), 644–651. https://doi.org/10.1016/j.jacc.2008.05.022. CrossRefPubMed

30.

White, H. L., Boer, R. A., Maqbool, A., Greenwood, D., Veldhuisen, D. J., Cuthbert, R., et al. (2003). An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. European Journal of Heart Failure, 5(4), 463–468. https://doi.org/10.1016/S1388-9842(03)00044-8. CrossRefPubMed

31.

The Beta-Blocker Evaluation of Survival Trial Investigators. (2001). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New England Journal of Medicine, 344(22), 1659–1667. https://doi.org/10.1056/NEJM200105313442202. CrossRef

32.

Zou, C.-H., Zhang, J., Zhang, Y.-H., Wei, B.-Q., Wu, X.-F., Zhou, Q., et al. (2014). Frequency and predictors of normalization of left ventricular ejection fraction in recent-onset nonischemic cardiomyopathy. The American Journal of Cardiology, 113(10), 1705–1710. https://doi.org/10.1016/j.amjcard.2014.02.028. CrossRefPubMed

Titel: Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure
Autoren:: Jasmine A. Luzum
Joseph D. English
Umair S. Ahmad
Jessie W. Sun
Benjamin D. Canan
Wolfgang Sadee
Joseph P. Kitzmiller
Philip F. Binkley
Publikationsdatum: 12.02.2019
DOI: https://doi.org/10.1007/s12265-019-09866-5
Verlag: Springer US
Zeitschrift: Journal of Cardiovascular Translational Research
Ausgabe 4/2019
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395

Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

21.02.2020 | TAVI | Medizin aktuell | Ausgabe 1/2020

TAVI auch schon für junge Patienten?

Akuter Schlaganfall: Erfolg durch spezielles Einsatzmobil im Rettungsdienst

In Kooperation mit:: Kardiologie.org

Diese Impfung könnte das Schlaganfall-Risiko verringern

In Kooperation mit:: Kardiologie.org

Neue Lipidleitlinien: Wie ist der strengere LDL-Zielwert in der Praxis erreichbar?

In Kooperation mit:: Kardiologie.org

weitere anzeigen

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Bildnachweise

Mail Icon II

Springer Medizin

Electronic supplementary material

Publisher’s Note

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Innere Medizin

Weitere Artikel der Ausgabe 4/2019

MicroRNA-29b-3p Targets SPARC Gene to Protect Cardiocytes against Autophagy and Apoptosis in Hypoxic-Induced H9c2 Cells

KC21 Peptide Inhibits Angiogenesis and Attenuates Hypoxia-Induced Retinopathy

Intra-aortic Balloon Counterpulsation for High-Risk Percutaneous Coronary Intervention: Defining Coronary Responders

A Durable Porcine Pericardial Surgical Bioprosthetic Heart Valve: a Proof of Concept

Correction to: Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data

Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers

Neu im Fachgebiet Kardiologie

TAVI auch schon für junge Patienten?

Akuter Schlaganfall: Erfolg durch spezielles Einsatzmobil im Rettungsdienst

Diese Impfung könnte das Schlaganfall-Risiko verringern

Neue Lipidleitlinien: Wie ist der strengere LDL-Zielwert in der Praxis erreichbar?

Newsletter